This website is for healthcare professionals only in the U.K. Prescribing information and Adverse Event reporting can be found at the bottom of the page.
Find out about our news on this page. Nuceiva® (botulinum toxin type A) is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.1
NUCEIVA should only be administered by healthcare practitioners with appropriate qualifications and expertise in the treatment of glabellar lines and the use of required equipment.
Beauty is truly evolving.
The science, the networking, and the conversations all reflect this shift. The exchange of perspectives, clinical insights, and forward‑looking ideas highlighted the growing focus on science‑driven solutions, responsible education, and patient‑centric approaches within the field.
Throughout the congress, our booth was a vibrant meeting point—buzzing with energy, ideas, and meaningful exchanges. It was a pleasure to reconnect with familiar faces while also welcoming new connections, all united by a shared commitment to advancing standards, education, and innovation in aesthetics. The enthusiasm and curiosity we encountered reinforced just how important collaboration and dialogue are in shaping what comes next.
Evolus sponsored educational activities at AMWC 2026. These events were intended for medical aesthetics healthcare professionals (excluding French‑registered HCPs) attending AMWC 2026.
Thank you to everyone who stopped by, shared insights, and contributed to making this year’s congress such a dynamic and inspiring experience.
See you next year!
Reporting forms and information can be found at yellowcard.mhra.gov.uk/ or search MHRA yellow card in the Google Play or Apple App Store.
Adverse events should also be reported to Evolus International Ltd.
Please contact Evolus Europe Medical Information by medicalinformation@evolus.com or calling 08000541302.
Evolus clinical trial details can be found here. For any additional information, please email medicalinformation@evolus.com
Evolus is unable to provide advice on personal medical matters. Please consult your healthcare professional for specific, health-related advice and support.Links to the electronic medicines compendium (emc) website to access the Patient Information Leaflets (PIL) and Summary of Product Characteristics (SmPC) for our medicine in the United Kingdom is also available here.
NUCEIVA PRESCRIBING INFORMATION
Legal category: POM. List price: 50 unit vial - £75.50
REPORTING OF SIDE EFFECTS FOR THE UNITED KINGDOM
Adverse events should be reported.Reporting forms and information can be found at yellowcard.mhra.gov.uk/ or search MHRA yellow card in the Google Play or Apple App Store.
Adverse events should also be reported to Evolus International Ltd.
Please contact Evolus Europe Medical Information by medicalinformation@evolus.com or calling 08000541302.
